Lv3
286 积分 2025-04-02 加入
胃癌生物标志物检测临床应用指南(2026版)
1个月前
已完结
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2个月前
已完结
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
2个月前
已完结
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
2个月前
已完结
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.Ramucirumab plus paclitaxel versus placebo plus paclitaxel for advanced gastric or gastro-oesophageal junction adenocarcinoma after previous chemotherapy (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
2个月前
已完结
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2个月前
已完结
The KEYNOTE-811 Trial of Pembrolizumab Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric/Gastroesophageal Junction Cancer
2个月前
已关闭
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
2个月前
已完结
Perioperative Pembrolizumab Plus Chemotherapy in Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Final Analysis of KEYNOTE-585
2个月前
已关闭